ALK and non-small cell lung carcinoma: Based on this trial, the National Medical Products Administration (NMPA) of China has approved toripalimab in combination with pemetrexed and platinum as the first-line treatment for patients with inoperable, locally advanced, or metastatic NSCLC that is negative for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK).